Unknown

Dataset Information

0

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study.


ABSTRACT: Merkel cell carcinoma (MCC) is a rare aggressive form of skin cancer originating in neuroendocrine cells. The antiprogrammed death ligand 1 (PD-L1) monoclonal antibody (mAb) avelumab has been approved for treatment of MCC, but options are limited, should it be ineffective as a monotherapy. Combined therapy with low/moderate dose nab-paclitaxel and an interleukin 15 (IL-15)-based therapeutic such as the IL-15 'superagonist' N-803 may increase response by activation of the immune system. The case of a 71-year-old man diagnosed with MCC who achieved and maintained a complete response (CR) by treatment with the anti-PD-L1 mAb avelumab in combination with IL-15 superagonist N-803 and nab-paclitaxel (Abraxane) is presented. Avelumab treatment alone resulted in a response in a para-aortic lesion, but not the other tumor masses. N-803 was added, followed by nab-paclitaxel; CT showed a decrease in the size of the abdominal mass at 1?month, near resolution at 3 months and CR at 5 months. Abraxane was discontinued after the first CR on CT, and the patient continues on avelumab/N-803 treatment and maintains a CR. Combination of avelumab with low/moderate-dose chemotherapy and an immune enhancer such as N-803 may offer a viable treatment option for MCC patients for whom avelumab therapy alone was not effective.

SUBMITTER: Drusbosky L 

PROVIDER: S-EPMC7484858 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study.

Drusbosky Leylah L   Nangia Chaitali C   Nguyen Andrew A   Szeto Christopher C   Newton Yulia Y   Spilman Patricia P   Reddy Sandeep Bobby SB  

Journal for immunotherapy of cancer 20200901 2


Merkel cell carcinoma (MCC) is a rare aggressive form of skin cancer originating in neuroendocrine cells. The antiprogrammed death ligand 1 (PD-L1) monoclonal antibody (mAb) avelumab has been approved for treatment of MCC, but options are limited, should it be ineffective as a monotherapy. Combined therapy with low/moderate dose nab-paclitaxel and an interleukin 15 (IL-15)-based therapeutic such as the IL-15 'superagonist' N-803 may increase response by activation of the immune system. The case  ...[more]

Similar Datasets

| S-EPMC7032639 | biostudies-literature
| S-EPMC5104912 | biostudies-literature
| S-EPMC5787870 | biostudies-literature
| S-EPMC5992862 | biostudies-literature
| S-EPMC5916319 | biostudies-literature
| S-EPMC6337786 | biostudies-literature
| S-EPMC5840183 | biostudies-literature
| S-EPMC8053152 | biostudies-literature
| S-EPMC6710317 | biostudies-literature
| S-EPMC1482584 | biostudies-literature